Sophia Shi: Decoding the role of sugar molecules in brain aging and neurodegenerative diseases

Résumé fourni par la source

Stanford Chemistry PhD graduate Sophia Shi reveals her pioneering journey decoding how sugar molecules protect aging brains in this Genomic Press Interview. Working under the mentorship of Nobel laureate Carolyn Bertozzi and renowned neurobiologist Tony Wyss-Coray, Dr. Shi has uncovered groundbreaking evidence that the brain's protective glycocalyx, a complex sugar coating on blood-brain barrier endothelial cells, deteriorates dramatically with age, contributing to cognitive decline and neurodegenerative diseases. Her recent Nature publication demonstrates that this “forest” of sugar molecules becomes sparse and degraded in aging brains, leading to blood-brain barrier dysfunction and neuroinflammation. Remarkably, her team demonstrated that restoring these critical mucin-type O-glycans in aged mice significantly improves barrier integrity and cognitive function, thereby opening up unprecedented therapeutic avenues for Alzheimer's disease and related conditions. Now launching her independent laboratory at Harvard's prestigious Rowland Institute directly from doctoral training, a rare achievement that speaks to her exceptional promise, Dr. Shi represents a new generation of interdisciplinary scientists seamlessly bridging glycobiology and neuroscience. From solving childhood puzzles in New Jersey to decoding molecular mysteries at Stanford, she shares candid insights on navigating scientific challenges, the transformative impact of supportive mentorship, building inclusive research environments, and her ambitious vision for developing glycan-based therapies to combat brain aging. Her recognition with the David S. Miller Young Scientist Award at the Cerebral Vascular Biology Conference underscores her emergence as a leading voice in understanding how post-translational modifications, particularly glycosylation, shape brain health, and resilience throughout the lifespan, offering tangible hope for millions affected by age-related cognitive decline and neurodegenerative diseases worldwide.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.